loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Dr Lal Pathlabs Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Dr. Lal Pathlabs Ltd. 24 Jul 2026 14:19 PM

Q1FY27 Quarterly Result Announced for Dr. Lal Pathlabs Ltd.

Healthcare Services company Dr. Lal Pathlabs announced Q1FY27 results

Consolidated Financial Highlights:

  • Revenue from operations for Q1FY27 stood at Rs 7,977 million, compared to Rs 7,027 million in Q4FY26, representing a QoQ growth of 13.52%. On a YoY basis, revenue increased by 19.10% from Rs 6,698 million in Q1FY26.
  • Total income for Q1FY27 was Rs 8,296 million, marking a 14.16% increase QoQ from Rs 7,267 million in Q4FY26 and an 18.87% increase YoY from Rs 6,979 million in Q1FY26.
  • Profit for the period reached Rs 1,705 million in Q1FY27, up 28.97% QoQ from Rs 1,322 million in Q4FY26 and up 27.24% YoY from Rs 1,340 million in Q1FY26.
  • Total comprehensive income for Q1FY27 was Rs 1,719 million, growing 25.93% QoQ from Rs 1,365 million in Q4FY26 and 29.15% YoY from Rs 1,331 million in Q1FY26.
  • Basic earnings per share (EPS) for Q1FY27 stood at Rs 10.15, compared to Rs 7.86 in Q4FY26 and Rs 7.94 in Q1FY26.

Standalone Financial Highlights:

  • Revenue from operations in Q1FY27 was Rs 7,644 million, reflecting a growth of 13.21% QoQ from Rs 6,752 million in Q4FY26 and a growth of 19.31% YoY from Rs 6,407 million in Q1FY26.
  • Total income for Q1FY27 stood at Rs 7,943 million, representing an increase of 11.53% QoQ from Rs 7,122 million in Q4FY26 and 19.09% YoY from Rs 6,670 million in Q1FY26.
  • Profit for the period was Rs 1,659 million in Q1FY27, up 17.58% QoQ compared to Rs 1,411 million in Q4FY26 and up 28.31% YoY compared to Rs 1,293 million in Q1FY26.
  • Total comprehensive income for Q1FY27 reached Rs 1,672 million, showing a growth of 14.99% QoQ from Rs 1,454 million in Q4FY26 and 30.22% YoY from Rs 1,284 million in Q1FY26.

Business Highlights:

  • Shahbazkers Acquisition: During the quarter, the Parent Company acquired a 100% stake in Shahbazkers Diagnostic Centre Private Limited (SDCPL) effective May 1, 2026, for a cash consideration of Rs 200 million. This acquisition resulted in a provisional goodwill of Rs 143 million.
  • Ghana Expansion: The Board approved the acquisition of an 80% equity stake in Sunshine Healthcare Limited (SHL), located in Ghana, for a consideration not exceeding GHS 45.60 million (equivalent to approximately Rs 380 million).
  • Neuome Technologies Investment: The Board approved a 30% equity stake subscription in Neuome Technologies Private Limited for a consideration not exceeding Rs 35.00 million. Neuome is engaged in developing innovative solutions for sample preservation and pre-analytical technologies.
  • Interim Dividend: The Board declared an interim dividend of Rs 5/- per equity share (50% on a face value of Rs 10/- each) for the financial year FY27.
  • Dubai Subsidiary: A wholly-owned subsidiary, Dr Lal Pathlabs FZCO, was incorporated in Dubai, UAE, during the quarter ended June 30, 2026.
  • Bonus Issue: EPS figures for Q1FY26 have been restated to reflect the impact of a 1:1 bonus share issue approved in December 2025.
  • Labour Code Impact (Historical): For the full year FY26, the company recorded an exceptional item of Rs 301.00 million (consolidated and standalone) as an incremental liability related to past service costs for gratuity and leave under the New Labour Codes.

Result PDF

Healthcare Services company Dr. Lal Pathlabs announced Q4FY26 results

  • Revenue increased by 16.6% in Q4FY26.
  • EBITDA for Q4FY26 increased by 10.5% with a margin of 26.6%.
  • PAT for Q4FY26 is Rs 132 crore. with a margin for of 18.8%.
  • Final Dividend of 40% i.e. Rs. 4 per share.
  • Cash and Cash equivalents as on 31st March, 2026 is Rs. 1,526 crore.

Result PDF

Healthcare Services company Dr. Lal Pathlabs announced Q3FY26 results

  • Revenue increased by 10.6% in Q3FY26 and by 10.8% for the nine months ended Dec’25.
  • EBITDA (before exceptional items) for Q3FY26 increased by 16.3% with a margin of 27.2%.
  • P&L for Q3FY26 includes an exceptional impact of Rs 30.1 crore on account of Labour codes.
  • PAT for Q3FY26 is Rs 91 crore. with a margin for of 13.9%.
  • Interim Dividend of Rs. 3.5 per share for Q3FY26.
  • Cash and Bank balances as on 31st Dec, 2025 is Rs. 1,411 crore.

Result PDF

Healthcare Services company Dr. Lal Pathlabs announced Q2FY26 results

  • Revenue: Rs 731 crore compared to Rs 660 crore during Q2FY25, change 10.7%.
  • EBITDA: Rs 224 crore compared to Rs 202 crore during Q2FY25, change 10.8%.
  • EBITDA Margin: 30.7% for Q2FY26.
  • PBT: Rs 204 crore compared to Rs 183 crore during Q2FY25, change 11.2%.
  • PAT: Rs 152 crore compared to Rs 131 crore during Q2FY25, change 16.4%.

Brig Dr Arvind Lal, Executive Chairman, said: “At Dr. Lal PathLabs, we see this decade as one for deep transformation. The burden of chronic and lifestyle-related diseases continues to rise, demanding greater focus on early detection and continuous monitoring. As new therapies for diabetes, hypertension and obesity become more widely available, the role of diagnostics will only intensify.

Further, as policy initiatives like Ayushman Bharat expand access across Tier-2 and Tier-3 regions, diagnostics is emerging as the essential first step in care delivery. The growing awareness around preventive health, supported by rapid digital adoption, is helping millions of citizens engage with organized healthcare for the first time. This convergence of accessibility, affordability, and accountability marks a defining moment for the sector, and we are privileged to play a prime role in it.

As the shift from unorganized to organized healthcare continues, we stand ready to lead the way responsibly and to contribute meaningfully to India’s ambition of universal healthcare.”

Shankha Banerjee, Chief Executive Officer, said: “Q2FY26 marked a healthy revenue growth trajectory on the back of a robust sample volume growth. As we continue to focus on improving patient service, enhancing medical expertise and network expansion, this momentum is expected to continue.

We continue to broaden our high-complexity testing capabilities, including Genomics, Oncology, Autoimmunity and others. We are also increasing applications for AI in our operations, including inhouse developed algorithms.

Digital and automation initiatives remain central to improving operational efficiency, enhancing patient experience, and supporting scalable growth.

Moving forward, growth will be underpinned by geographic expansion, portfolio innovation and digital enablement. Our pricing discipline continues to serve as a powerful lever, and is expected to support movement from unorganized to organized players.

Our operational priority remains to maximize network utilization and convert infrastructure into significant operating leverage, ensuring we deliver superior, sustainable, and profitable growth for our shareholders.”

Ved Prakash Goel, Group CFO & CEO, said: “Q2FY26 demonstrated steady growth in volumes and favourable business mix, driving sustained financial performance. By maintaining disciplined execution, cost efficiency and a calibrated pricing approach, we have maintained profitability while retaining strategic flexibility for future investments.

During the quarter, we further expanded our footprint across underpenetrated markets, supported by new labs and PSCs, while reinforcing engagement with channel partners. This tiered expansion strategy, coupled with completion of back-end integration and merger of Suburban Diagnostics, is helping us unlock new demand pockets and strengthen our leadership in core regions, including Delhi NCR, Mumbai, Pune, and Goa. Strategic digital investments continue to yield tangible ROI.

Looking ahead, with a robust balance sheet, strategic investments in technology, and a clearly defined growth roadmap, we are confident of delivering sustainable longterm value and capturing the shift from unorganized to organized diagnostics across India.”

Result PDF

Healthcare Services company Dr. Lal Pathlabs announced Q1FY26 results

  • Revenue increased by 11.3% in Q1FY26 to Rs 670 crore.
  • EBITDA increased by 13.1% with a margin of 28.7%.
  • PAT increased by 24.3% to Rs 134 crore, with a margin for of 20.0%.
  • Interim Dividend of Rs 6 per share for Q1FY26.

Result PDF

Healthcare Services company Dr. Lal Pathlabs announced Q4FY25 results

  • Revenue: Rs 603 crore compared to Rs 545 crore during Q4FY24, change 10.5%.
  • EBITDA: Rs 169 crore compared to Rs 145 crore during Q4FY24, change 16.9%.
  • EBITDA margin: 28.1% for Q4FY25.
  • PAT: Rs 156 crore compared to Rs 86 crore during Q4FY24, change 81.4%.
  • PAT margin: 25.8% for Q4FY25.
  • Fourth Interim Dividend of Rs 6 per share for FY25.

Result PDF

Healthcare Services company Dr. Lal Pathlabs announced Q3FY25 results

  • Revenue increased by 10.7% from Rs 597 crore in Q3FY25 to Rs 539 crore in Q3FY24..
  • EBITDA increased by 9.6% from Rs 154 crore in Q3FY25 to Rs 141 crore in Q3FY24, with a margin of 25.8%.
  • PAT increased by 19.3% from Rs 98 crore in Q3FY25 to Rs 82 crore in Q3FY24, with a margin for of 16.4%.
  • Third Interim Dividend of Rs. 6 per share for FY25.

Result PDF

Healthcare Services company Dr. Lal Pathlabs announced Q2FY25 results

  • Revenue increased by 9.8% in Q2FY25, Rs 660 crore compared to Rs 601 crore during Q2FY24.
  • EBITDA increased by 13.9% with a margin of 30.7%.
  • PAT increased by 18.1% with a margin for of 19.8%.
  • Second Interim Dividend of Rs 6 per share for FY25

Result PDF

Healthcare Services company Dr. Lal Pathlabs announced Q1FY25 results:

  • Revenue increased by 11.3% in Q1FY25 to Rs 602 crore
  • EBITDA increased by 16.2% with a margin of 28.2%
  • PAT increased by 29.1% to Rs 108 crore with a margin for of 17.9%
  • Interim Dividend of Rs 6 per share for FY 2024-25 

Result PDF

Healthcare Services company Dr. Lal PathLabs announced Q4FY24 results:

  • Revenue increased by 11.1% in Q4FY24
  • EBITDA increased by 25.1% with a margin of 26.5%
  • PAT increased by 50.8% with a margin for of 15.7%

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app